ArticleInternational journal of endocrinology and metabolism2013
Non-contraceptive benefits of oral hormonal contraceptives.
Article in International journal of endocrinology and metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.
- Endometrial hyperplasia as a risk factor of endometrial cancer.Archives of gynecology and obstetrics · 2022Pooled it
- Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime.BMC women's health · 2020Trial
- Article
- Hormonal profiles of eumenorrheic women compared to hormonal intrauterine device users.Physiological reports · 2026Article
- An evolutionary medicine perspective on the design of non-hormonal contraceptives for women.Evolution, medicine, and public health · 2026Article
- Progestins - a review of clinical application in gynecology.Annals of medicine · 2025Review
- [Un]met Need and [Un]wanted Family Planning: A Cross-Sectional Study Among Women in Argentina, Ghana, and India Examining Characteristics, Reasons, and Alignment With Fertility Desires.Studies in family planning · 2025Article
- Associations of adolescent menstrual symptoms with school absences and educational attainment: analysis of a prospective cohort study.NPJ science of learning · 2025Article
- Pharmacological and Non-Pharmacological Interventions for Polycystic Ovary Syndrome (PCOS) in Indian Women: A Systematic Review and Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Differences in anxiety, worry, and perceived stress among naturally cycling women and oral contraceptives users: a cross-sectional study investigating the role of contraceptive types.Archives of women's mental health · 2024Article
- Gap in knowledge of health benefits and risks of combined oral contraceptives among Lebanese women.BMC public health · 2024Article
- The benefits of estetrol addition to drospirenone for contraception.AJOG global reports · 2023Article
- Oral Contraceptive Pills and Hypertension: A Review of Current Evidence and Recommendations.Hypertension (Dallas, Tex. : 1979) · 2023Review
- A Multi-Institutional Informed Consent Proposal as a Prevention Tool for Combined Oral Contraceptive Intake and Thrombotic Risk.Journal of personalized medicine · 2023Review
- Contraceptives Are Also Drugs.Cureus · 2023Article
- Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients.Biomedicines · 2022Review
- A prospective analysis of the relationship between sexual acceptability and contraceptive satisfaction over time.American journal of obstetrics and gynecology · 2022Article
- Hypertension in Women: A South-Asian Perspective.Frontiers in cardiovascular medicine · 2022Review
- Article
- Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.Geburtshilfe und Frauenheilkunde · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is becoming evident that oral hormonal contraceptives-besides being well established contraceptives-seem to become important medications for many functional or organic disturbances. So far, clinical effectiveness has been shown for treatment as well as prevention of menstrual bleeding disorders and menstrual-related pain symptoms. Also this is true for premenstrual syndrome (PMS) and premenstrual disphoric disorder (PMDD). Particular oral contraceptives (OCs) containing anti-androgenic progestogens were shown to be effective medications for treatment of androgenisation symptoms (seborrhea, acne, hirsutism, alopecia). Through perfect suppression of the hypothalamic-pituitary-ovarian axis OCs have proven to be effective in elimination of persistent follicular cysts. Endometriosis/adenomyosis related pain symptoms are well handled similar to other drugs like Gonadotropine Releasing Hormone agonists but are less expensive, with less side effects, and possibility to be used for longer periods of time. This is also true for myoma. Pelvic inflammatory disease, rheumatoid arthritis, menstrual migraine, and onset of multiple sclerosis are prevented or delayed. Bone density is preserved and asthma symptoms improved. Endometrial hyperplasia and benign breast disease can be controlled. There is definitely a significant impact on risk reduction regarding endometrial, ovarian, and colon cancers. In conclusion, it needs to be recognized that oral combined hormonal contraceptives (estrogen/ progestogen combination) are - besides being reliable forms of contraception - are cost-effective medications for many medical disorders in women. Therefore, these contraceptives drugs are important for female and global health and should be used in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.